- StatPearls [BOOK]
- BOOKStatPearls Publishing: Treasure Island (FL)
- Succinylcholine chloride is a short-acting depolarizing neuromuscular blockade that is approved by the United States Food and Drug Administration (FDA) as a provision to other sedatives or hypnotics....
Succinylcholine chloride is a short-acting depolarizing neuromuscular blockade that is approved by the United States Food and Drug Administration (FDA) as a provision to other sedatives or hypnotics. It is a correlate of acetylcholine (ACh); hence, it disrupts all cholinergic receptors of the parasympathetic and sympathetic nervous systems. Its use can expedite rapid endotracheal intubation, facilitate surgical procedures, and aid in mechanical ventilation by relaxation of skeletal muscles. Due to its rapid onset and short mechanism of action, it is the drug of choice in emergency situations where immediate airway management is required. The drug's rapid onset allows for quick intervention and control of the airway, and its short duration is advantageous when endotracheal intubation can not be achieved. The skeletal muscle relaxation provided by succinylcholine is beneficial during certain surgical procedures, more specifically, when abdominal wall muscle disruption is necessary, mechanical ventilation is difficult or defied, or in surgical cases where spontaneous respiration of the patient is counterproductive to the current situation.
- Emergency Department Intubation Success With Succinylcholine Versus Rocuronium: A National Emergency Airway Registry Study. [Journal Article]
- AEAnn Emerg Med 2018 May 07
- CONCLUSIONS: In this large observational series, we did not detect an association between paralytic choice and first-pass rapid sequence intubation success or peri-intubation adverse events.
- Moving anesthesiology educational resources to the point of care: experience with a pediatric anesthesia mobile app. [Journal Article]
- KJKorean J Anesthesiol 2018 May 09
- CONCLUSIONS: Real-time in-app analytics helped elucidate the actual usage of this educational resource and will guide future decisions regarding development and educational content. Further research is required to determine learners' preferred choice of device, user experience, and content in the full range of clinical and nonclinical purposes.
- Malignant Hyperthermia: Review of Diagnosis and Treatment during Cardiac Surgery with Cardiopulmonary Bypass. [Review]
- JCJ Cardiothorac Vasc Anesth 2018 Mar 20
- Malignant hyperthermia is a potentially life-threatening hypermetabolic disorder, often induced by exposure to volatile anesthetics and succinylcholine. There are few reports of malignant hyperthermi...
Malignant hyperthermia is a potentially life-threatening hypermetabolic disorder, often induced by exposure to volatile anesthetics and succinylcholine. There are few reports of malignant hyperthermia during cardiopulmonary bypass. Here the authors review available literature including case reports of malignant hyperthermia and cardiopulmonary bypass and discuss the potential implications of malignant hyperthermia diagnosis and management as it applies to cardiac surgery.
- GeneReviews® [BOOK]
- BOOKUniversity of Washington, Seattle: Seattle (WA)
- The dystrophinopathies cover a spectrum of X-linked muscle disease ranging from mild to severe that includes Duchenne muscular dystrophy, Becker muscular dystrophy, and DMD-associated dilated cardiom...
The dystrophinopathies cover a spectrum of X-linked muscle disease ranging from mild to severe that includes Duchenne muscular dystrophy, Becker muscular dystrophy, and DMD-associated dilated cardiomyopathy (DCM). The mild end of the spectrum includes the phenotypes of asymptomatic increase in serum concentration of creatine phosphokinase (CK) and muscle cramps with myoglobinuria. The severe end of the spectrum includes progressive muscle diseases that are classified as Duchenne/Becker muscular dystrophy when skeletal muscle is primarily affected and as DMD-associated dilated cardiomyopathy (DCM) when the heart is primarily affected. Duchenne muscular dystrophy (DMD) usually presents in early childhood with delayed motor milestones including delays in walking independently and standing up from a supine position. Proximal weakness causes a waddling gait and difficulty climbing stairs, running, jumping, and standing up from a squatting position. DMD is rapidly progressive, with affected children being wheelchair dependent by age 12 years. Cardiomyopathy occurs in almost all individuals with DMD after age 18 years. Few survive beyond the third decade, with respiratory complications and progressive cardiomyopathy being common causes of death. Becker muscular dystrophy (BMD) is characterized by later-onset skeletal muscle weakness. With improved diagnostic techniques, it has been recognized that the mild end of the spectrum includes men with onset of symptoms after age 30 years who remain ambulatory even into their 60s. Despite the milder skeletal muscle involvement, heart failure from DCM is a common cause of morbidity and the most common cause of death in BMD. Mean age of death is in the mid-40s. DMD-associated DCM is characterized by left ventricular dilation and congestive heart failure. Females heterozygous for a DMD pathogenic variant are at increased risk for DCM.
- Fluorescent Determination of Succinylcholine Chloride by Naphthalimide/ Stilbazolium Dye ⊂ CP5A. [Journal Article]
- JFJ Fluoresc 2018 Apr 23
- Succinylcholine Chloride (SCC), a short-acting neuromuscular relaxant, is non-fluorescent in aqueous solutions. This property makes it impossible to be determined by direct fluorescent method. Naphth...
Succinylcholine Chloride (SCC), a short-acting neuromuscular relaxant, is non-fluorescent in aqueous solutions. This property makes it impossible to be determined by direct fluorescent method. Naphthalimide dye (NA) exhibits very strong fluorescence emissions in aqueous solution, after complexing with carboxylatopillararene (CP5A) in aqueous solutions, the fluorescent quenched intensity of complex was observed. On the contraty, stilbazolium dye (SA) exhibits weak fluorescence emissions in aqueous solution, after being included by CP5A, a fluorescence enhancement was observed. However, adding SCC to the NA⊂ CP5A or SA⊂ CP5A complex solution led to the recovery of the fluorescence intensity, in the meantime, the color of SA⊂ CP5A solution changed from dark yellow to light yellow. The competitive supramolecular interaction between SCC, NA and SA for CP5A was studied by spectrofluorometry, 1H NMR. Herein, a FID (fluorescence indicator displacement) system to detect SCC based on NA⊂ CP5A and SA⊂ CP5A complex was developed.
- Delaying initiation of electroconvulsive treatment after administration of the anaesthetic agent and muscle relaxant reduces the necessity of re-stimulation. [Journal Article]
- NJNord J Psychiatry 2018 Apr 16; :1-6
- CONCLUSIONS: We found an association between an increased time interval from administration of thiopental and succinylcholine to ECT and a lowered risk of re-stimulations. The current study substantially strengthens the evidence on the benefits of delaying ECT after administration of anaesthetic agent and muscle relaxant.
- Effect of dexmedetomidine infusion on hemodynamic responses in microsurgery of larynx. [Journal Article]
- JAJ Anaesthesiol Clin Pharmacol 2018 Jan-Mar; 34(1):51-57
- CONCLUSIONS: Dexmedetomidine infusion attenuates the hemodynamic stress response during laryngoscopy, intubation, and microlaryngeal surgery and is associated better recovery profile.
- A novel mutation in the BCHE gene and phenotype identified in a child with low butyrylcholinesterase activity: a case report. [Journal Article]
- BMBMC Med Genet 2018 Apr 10; 19(1):58
- CONCLUSIONS: Double heterozygous recessive mutations are the cause of BChE deficiency of this boy in this study, including a novel mutation c.73A > T. Intellectual disability is a new phenotype that is probably associated with this mutation.
New Search Next
- StatPearls [BOOK]
- BOOKStatPearls Publishing: Treasure Island (FL)
- Vecuronium Bromide is an FDA approved peripherally acting muscle relaxant used for general anesthesia, endotracheal intubation, and ICU paralysis to facilitate mechanical ventilation in adequately se...
Vecuronium Bromide is an FDA approved peripherally acting muscle relaxant used for general anesthesia, endotracheal intubation, and ICU paralysis to facilitate mechanical ventilation in adequately sedated patients. This nondepolarizing neuromuscular blocking agent is often used as an adjustment to general anesthesia in patients anesthetized with isoflurane and enflurane. It is also used as an adjunct to succinylcholine when performing endotracheal intubation.